Fluid and electrolyte disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests, rarely hepatocellular neoplasms and peliosis hepatis (see WARNINGS ).
Hematologic: Suppression of clotting factors II, V, VII, and X, bleeding in patients on concomitant anticoagulant therapy, and polycythemia.
Nervous system: Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia.
Allergic: Hypersensitivity, including skin manifestations and anaphylactoid reactions.
Vascular Disorders: venous thromboembolism
Miscellaneous: Inflammation and pain at the site of intramuscular injection.
The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) medication guide for Testosterone. For Testosterone Undecanoate, REMS includes elements to assure safe use and implementation system . For additional information: /REMS
US BOXED WARNINGS :
Pulmonary Oil Microembolism (POME) Reactions And Anaphylaxis :
-Serious POME reactions, involving urge to cough, dyspnea, throat tightening, chest pain, dizziness, and syncope; and episodes of anaphylaxis, including life-threatening reactions, have been reported to occur during or immediately after the administration of testosterone undecanoate injection. These reactions can occur after any injection of testosterone undecanoate during the course of therapy, including after the first dose.
-Following each injection of testosterone undecanoate observe patients in the healthcare setting for 30 minutes in order to provide appropriate medical treatment in the event of serious POME reactions or anaphylaxis.
Secondary Exposure To Topical Testosterone :
-Virilization has been reported in children who were secondarily exposed to topical testosterone products.
-Children should avoid contact with unwashed or unclothed application sites in men using testosterone topical.
-Healthcare providers should advise patients to strictly adhere to recommended instructions for use.
Safety and efficacy have not been established in patients younger than 18 years.
Testosterone Enanthate and Testosterone Implant are indicated for delayed puberty in adolescent patients.
Testosterone Cypionate: Safety and efficacy have not been established in patients younger than 12 years.
Consult WARNINGS section for additional precautions.
As a result, Trenbolone Acetate now functions as the primary anabolic compound (aka the ‘workhorse’ compound) that will function to provide the muscle growth throughout the cycle. Trenbolone is strictly an advanced level anabolic steroid, unfit for use by beginners of any type. In this cycle, the Acetate variant of Trenbolone is utilized simply due to its seamless compatibility with Testosterone Propionate. This is because the Propionate and Acetate esters as, previously mentioned early on in this section of the profile, both possess almost identical half-lives (3 days for Trenbolone Acetate and days for Testosterone Propionate). This therefore provides an ease of convenience for the user, as well as smoother injection and administration frequencies. The fact that Testosterone is being utilized at a low enough doses to avoid aromatization, combined with the fact that Trenbolone’s inability to convert into Estrogen at any dose should result in the total elimination of any potential water retention, bloating, gynecomastia or any side effects associated with Estrogen . It is important to note that this cycle in particular is strong enough to be utilized as a bulking cycle, lean mass cycle, or cutting cycle – all without the inflated potential for water retention or other Estrogenic side effects.